- Home
- ICMB vs OCUP Comparison
ICMB vs OCUP Comparison
Compare ICMB & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICMB
- OCUP
- Stock Information
- Founded
- ICMB 2012
- OCUP 2018
- Country
- ICMB United States
- OCUP United States
- Employees
- ICMB N/A
- OCUP N/A
- Industry
- ICMB Finance: Consumer Services
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- ICMB Finance
- OCUP Health Care
- Exchange
- ICMB Nasdaq
- OCUP Nasdaq
- Market Cap
- ICMB 48.0M
- OCUP 53.1M
- IPO Year
- ICMB N/A
- OCUP N/A
- Fundamental
- Price
- ICMB $3.18
- OCUP $1.27
- Analyst Decision
- ICMB
- OCUP Strong Buy
- Analyst Count
- ICMB 0
- OCUP 3
- Target Price
- ICMB N/A
- OCUP $18.67
- AVG Volume (30 Days)
- ICMB 28.7K
- OCUP 92.8K
- Earning Date
- ICMB 11-11-2024
- OCUP 11-11-2024
- Dividend Yield
- ICMB 15.09%
- OCUP N/A
- EPS Growth
- ICMB N/A
- OCUP N/A
- EPS
- ICMB N/A
- OCUP N/A
- Revenue
- ICMB $23,878,302.00
- OCUP $16,449,000.00
- Revenue This Year
- ICMB $10.32
- OCUP N/A
- Revenue Next Year
- ICMB N/A
- OCUP $258.69
- P/E Ratio
- ICMB N/A
- OCUP N/A
- Revenue Growth
- ICMB N/A
- OCUP N/A
- 52 Week Low
- ICMB $2.98
- OCUP $1.15
- 52 Week High
- ICMB $4.04
- OCUP $3.50
- Technical
- Relative Strength Index (RSI)
- ICMB 51.32
- OCUP 44.79
- Support Level
- ICMB $3.14
- OCUP $1.24
- Resistance Level
- ICMB $3.22
- OCUP $1.34
- Average True Range (ATR)
- ICMB 0.08
- OCUP 0.08
- MACD
- ICMB 0.01
- OCUP 0.00
- Stochastic Oscillator
- ICMB 61.17
- OCUP 12.00
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.